SIFROL Pramipexole Dihydrochloride Monohydrate 250mcg Tablet 1's
RXDRUG-DR-XY27922-1pc
Discreet Packaging
FDA-registered Products
FDA-licensed Pharmacies
Indications/Uses
Pramipexole dihydrochloride monohydrate (Sifrol) tablets are indicated in the treatment of signs and symptoms of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa.
Pramipexole dihydrochloride monohydrate (Sifrol) tablets are indicated for the symptomatic treatment of idiopathic Restless Legs Syndrome.
Pramipexole dihydrochloride monohydrate (Sifrol) tablets are indicated for the symptomatic treatment of idiopathic Restless Legs Syndrome.
Dosage/Direction for Use
Dosage/Direction for Use
(All dose information refers to pramipexole salt form).
Parkinson's disease: Dosage: Initial treatment: As shown as follows dosages should be increased gradually from a starting dose of 0.375 mg per day and then increased every 5 - 7 days. Providing patients do not experience intolerable side effects, the dosage should be titrated to achieve a maximal therapeutic effect. (See Table 1.)
Parkinson's disease: Dosage: Initial treatment: As shown as follows dosages should be increased gradually from a starting dose of 0.375 mg per day and then increased every 5 - 7 days. Providing patients do not experience intolerable side effects, the dosage should be titrated to achieve a maximal therapeutic effect. (See Table 1.)
If a further dose increase is necessary the daily dose should be increased by 0.75 mg at weekly intervals up to a maximum dose of 4.5 mg per day.
Maintenance treatment: The individual dose should be in the range of 0.375 mg to a maximum of 4.5 mg per day. During dose escalation in pivotal studies both in early and advanced disease efficacy was observed starting at a daily dose of 1.5 mg. This does not preclude that in individual patients doses higher than 1.5 mg per day can result in additional therapeutic benefit. This applies particularly to patients with advanced disease where a reduction of the levodopa therapy is intended.
Treatment discontinuation: Pramipexole dihydrochloride monohydrate (Sifrol) tablets should be tapered off at a rate of 0.75 mg per day until the daily dose has been reduced to 0.75 mg. Thereafter the dose should be reduced by 0.375 mg per day (see Precautions).
Dosing in patients with concomitant levodopa therapy: In patients with concomitant levodopa therapy it is recommended that the dosage of levodopa is reduced during both dose escalation and maintenance treatment with pramipexole dihydrochloride monohydrate (Sifrol). This may be necessary in order to avoid excessive dopaminergic stimulation.
Dosing in patients with renal impairment: The elimination of pramipexole is dependent on renal function. The following dosage schedule is suggested for initiation of therapy: Patients with a creatinine clearance above 50 mL/min require no reduction in daily dose or dosing frequency.
Tablets: In patients with a creatinine clearance between 20 and 50 mL/min, the initial daily dose of pramipexole dihydrochloride monohydrate (Sifrol) tablets should be administered in two divided doses, starting at 0.125 mg twice a day (0.25 mg daily). A maximum daily dose of 2.25 mg pramipexole should not be exceeded.
In patients with a creatinine clearance less than 20 mL/min, the daily dose of pramipexole dihydrochloride monohydrate (Sifrol) tablets should be administered in a single dose, starting at 0.125 mg daily. A maximum daily dose of 1.5 mg pramipexole should not be exceeded.
If renal function declines during maintenance therapy reduce pramipexole dihydrochloride monohydrate (Sifrol) daily dose by same percentage as decline in creatinine clearance, i.e. if creatinine clearance declines by 30%, then reduce pramipexole dihydrochloride monohydrate (Sifrol) daily dose by 30%. The daily dose can be administered in two divided doses if creatinine clearance is between 20 and 50 mL/min and as a single daily dose if creatinine clearance is less than 20 mL/min.
Dosing in patients with hepatic impairment: Dose reduction is not considered necessary in patients with hepatic impairment.
Method of Administration: Tablets: The tablets should be taken orally, swallowed with water, and can be taken either with or without food.
The daily dosage is administered in equally divided doses 3x per day.
Restless Legs Syndrome: Dosage: The recommended starting dose of pramipexole dihydrochloride monohydrate (Sifrol) is 0.125 mg taken once daily 2 - 3 hours before bedtime. For patients requiring additional symptomatic relief, the dose may be increased every 4 - 7 days to a maximum of 0.75 mg per day (as shown in the table as follows). (See Table 2.)
Treatment discontinuation: Pramipexole dihydrochloride monohydrate (Sifrol) can be discontinued without tapered dose reduction. In a 26 week placebo controlled clinical trial, rebound of RLS symptoms (worsening of symptom severity as compared to baseline) was observed in 10% of patients (14 out of 135) after abrupt discontinuation of pramipexole. This effect was found to be similar across all doses.
Dosing in patients with renal impairment: The elimination of pramipexole dihydrochloride monohydrate (Sifrol) is dependent on renal function and closely related to the creatinine clearance. Based on a pharmacokinetic study in renally impaired subjects, patients with a creatinine clearance above 20 mL/min require no reduction in daily dose. The use of pramipexole dihydrochloride monohydrate (Sifrol) in RLS patients with renal impairment has not been studied.
Dosing in patients with hepatic impairment: Dose reduction is not considered necessary in patients with hepatic impairment, as approx. 90% of absorbed drug is excreted through the kidneys.
Dosing in children and adolescents: Safety and efficacy of pramipexole dihydrochloride monohydrate (Sifrol) have not been established in children and adolescents up to 18 years.
Method of Administration: The tablets should be taken orally, swallowed with water, and can be taken either with or without food.
Overdosage
Symptoms: There is no clinical experience with massive overdose. The expected adverse events should be those related to the pharmacodynamic profile of a dopamine agonist including nausea, vomiting, hyperkinesia, hallucinations, agitation and hypotension.
Therapy: There is no established antidote for overdose of a dopamine agonist. If signs of central nervous system stimulation are present, a neuroleptic agent may be indicated. Management of the overdose may require general supportive measures along with gastric lavage, intravenous fluids, and electrocardiogram monitoring.
Haemodialysis has not been shown to be helpful.
Therapy: There is no established antidote for overdose of a dopamine agonist. If signs of central nervous system stimulation are present, a neuroleptic agent may be indicated. Management of the overdose may require general supportive measures along with gastric lavage, intravenous fluids, and electrocardiogram monitoring.
Haemodialysis has not been shown to be helpful.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity to pramipexole or any other component of the product.
Special Precautions
Renal Impairment: When prescribing pramipexole dihydrochloride monohydrate (Sifrol) in a patient with renal impairment a reduced dose is suggested in line with Dosage & Administration.
Hallucinations and abnormal behaviour: Hallucinations and confusion are known side effects of treatment with dopamine agonists and levodopa in Parkinson's disease patients.
Hallucinations were more frequent when pramipexole dihydrochloride monohydrate (Sifrol) was given in combination with levodopa in Parkinson's disease patients with advanced disease than in monotherapy in Parkinson's disease patients with early disease. Within the RLS clinical development program for registration, one case of hallucinations has been reported.
Patients should be informed that (mostly visual) hallucinations can occur.
Patients should be aware of the fact that hallucinations can occur and may adversely affect their ability to drive.
Patients and caregivers should be aware of the fact that abnormal behaviour (reflecting symptoms of impulse control disorders and compulsive behaviours) such as binge eating, compulsive shopping, hypersexuality and pathological gambling have been reported in patients treated with dopaminergic drugs. Dose reduction/tapered discontinuation should be considered.
Patients with psychotic disorders: Patients with psychotic disorders should be treated with dopamine agonists only if the potential benefits outweigh the risks. Co-administration of antipsychotic medicinal products with pramipexole is not recommended, e.g. if dopamine-antagonistic effects can be expected.
Sudden onset of sleep and somnolence: Patients should be alerted to the potential sedating effects associated with pramipexole dihydrochloride monohydrate (Sifrol), including somnolence and the possibility of falling asleep while engaged in activities of daily living. Since somnolence is a frequent adverse event with potentially serious consequences, patients should neither drive a car nor operate other complex machinery until they have gained sufficient experience with pramipexole dihydrochloride monohydrate (Sifrol) to gauge whether or not it affects their mental and/or motor performance adversely. Patients should be advised that if increased somnolence or episodes of falling asleep during activities of daily living (e.g. conversations, eating, etc.) are experienced at any time during treatment, they should not drive or participate in potentially dangerous activities and should contact their physician.
Postural hypotension: In case of severe cardiovascular disease, care should be taken. It is recommended to monitor blood pressure, especially at the beginning of treatment, due to the general risk of postural hypotension associated with dopaminergic therapy.
Dystonia: Patients with Parkinson's disease may present with axial dystonia such as antecollis, camptocormia or pleurothotonus (Pisa Syndrome). Dystonia has occasionally been reported following initiation of dopamine agonists including pramipexole, although a clear causal relationship has not been established. Dystonia may also occur several months following medication initiation or adjustment. If dystonia occurs, the dopaminergic medication regimen should be reviewed and an adjustment considered.
Treatment discontinuation in Parkinson's disease: Symptoms suggestive of a neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy (see Dosage & Administration).
Drug withdrawal syndrome: A drug withdrawal syndrome has been reported during or after discontinuation of dopamine agonists including pramipexole. Risk factors may include high cumulative dopaminergic exposure. Withdrawal symptoms do not respond to levodopa, and may include apathy, anxiety, depression, fatigue, sweating and pain. Prior to discontinuation, patients should be informed about potential withdrawal symptoms, and closely monitored during and after discontinuation. In case of severe withdrawal symptoms, temporary re-administration of a dopamine agonist at the lowest effective dose may be considered.
Melanoma: Epidemiological studies have shown that patients with Parkinson's disease have a higher risk (2- to approximately 6-fold higher) of developing melanoma than the general population.
Whether the increased risk observed was due to Parkinson's disease or other factors, such as drugs used to treat Parkinson's disease, is unclear.
For the reasons stated previously, patients and providers are advised to monitor for melanoma when using pramipexole or other dopaminergic drugs.
Retinal changes in albino rats: Pathologic changes (degeneration and loss of photoreceptor cells) were observed in the retina of albino rats in the 2-years carcinogenicity study. Evaluation of the retinas of albino mice, pigmented rats, monkeys, and minipigs did not reveal similar changes. The potential significance of this effect in humans has not been established, but cannot be disregarded because disruption of a mechanism that is universally present in vertebrates (i.e. disk shedding) may be involved.
Augmentation in RLS: Reports in the literature indicate that treatment of RLS with dopaminergic medications can result in augmentation.
Augmentation refers to the earlier onset of symptoms in the evening (or even the afternoon), increase in symptoms, and spread of symptoms to involve other extremities. Augmentation was specifically investigated in a controlled clinical trial over 26 weeks. Kaplan-Meier analysis of time to augmentation showed no significant difference between pramipexole (N = 152) and placebo groups (N = 149).
Driving and Using Machines: Patients should be aware of the fact that hallucinations can occur and may adversely affect their ability to drive.
Patients should be alerted to the potential sedating effects associated with pramipexole dihydrochloride monohydrate (Sifrol), including somnolence and the possibility of falling asleep while engaged in activities of daily living.
Hallucinations and abnormal behaviour: Hallucinations and confusion are known side effects of treatment with dopamine agonists and levodopa in Parkinson's disease patients.
Hallucinations were more frequent when pramipexole dihydrochloride monohydrate (Sifrol) was given in combination with levodopa in Parkinson's disease patients with advanced disease than in monotherapy in Parkinson's disease patients with early disease. Within the RLS clinical development program for registration, one case of hallucinations has been reported.
Patients should be informed that (mostly visual) hallucinations can occur.
Patients should be aware of the fact that hallucinations can occur and may adversely affect their ability to drive.
Patients and caregivers should be aware of the fact that abnormal behaviour (reflecting symptoms of impulse control disorders and compulsive behaviours) such as binge eating, compulsive shopping, hypersexuality and pathological gambling have been reported in patients treated with dopaminergic drugs. Dose reduction/tapered discontinuation should be considered.
Patients with psychotic disorders: Patients with psychotic disorders should be treated with dopamine agonists only if the potential benefits outweigh the risks. Co-administration of antipsychotic medicinal products with pramipexole is not recommended, e.g. if dopamine-antagonistic effects can be expected.
Sudden onset of sleep and somnolence: Patients should be alerted to the potential sedating effects associated with pramipexole dihydrochloride monohydrate (Sifrol), including somnolence and the possibility of falling asleep while engaged in activities of daily living. Since somnolence is a frequent adverse event with potentially serious consequences, patients should neither drive a car nor operate other complex machinery until they have gained sufficient experience with pramipexole dihydrochloride monohydrate (Sifrol) to gauge whether or not it affects their mental and/or motor performance adversely. Patients should be advised that if increased somnolence or episodes of falling asleep during activities of daily living (e.g. conversations, eating, etc.) are experienced at any time during treatment, they should not drive or participate in potentially dangerous activities and should contact their physician.
Postural hypotension: In case of severe cardiovascular disease, care should be taken. It is recommended to monitor blood pressure, especially at the beginning of treatment, due to the general risk of postural hypotension associated with dopaminergic therapy.
Dystonia: Patients with Parkinson's disease may present with axial dystonia such as antecollis, camptocormia or pleurothotonus (Pisa Syndrome). Dystonia has occasionally been reported following initiation of dopamine agonists including pramipexole, although a clear causal relationship has not been established. Dystonia may also occur several months following medication initiation or adjustment. If dystonia occurs, the dopaminergic medication regimen should be reviewed and an adjustment considered.
Treatment discontinuation in Parkinson's disease: Symptoms suggestive of a neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy (see Dosage & Administration).
Drug withdrawal syndrome: A drug withdrawal syndrome has been reported during or after discontinuation of dopamine agonists including pramipexole. Risk factors may include high cumulative dopaminergic exposure. Withdrawal symptoms do not respond to levodopa, and may include apathy, anxiety, depression, fatigue, sweating and pain. Prior to discontinuation, patients should be informed about potential withdrawal symptoms, and closely monitored during and after discontinuation. In case of severe withdrawal symptoms, temporary re-administration of a dopamine agonist at the lowest effective dose may be considered.
Melanoma: Epidemiological studies have shown that patients with Parkinson's disease have a higher risk (2- to approximately 6-fold higher) of developing melanoma than the general population.
Whether the increased risk observed was due to Parkinson's disease or other factors, such as drugs used to treat Parkinson's disease, is unclear.
For the reasons stated previously, patients and providers are advised to monitor for melanoma when using pramipexole or other dopaminergic drugs.
Retinal changes in albino rats: Pathologic changes (degeneration and loss of photoreceptor cells) were observed in the retina of albino rats in the 2-years carcinogenicity study. Evaluation of the retinas of albino mice, pigmented rats, monkeys, and minipigs did not reveal similar changes. The potential significance of this effect in humans has not been established, but cannot be disregarded because disruption of a mechanism that is universally present in vertebrates (i.e. disk shedding) may be involved.
Augmentation in RLS: Reports in the literature indicate that treatment of RLS with dopaminergic medications can result in augmentation.
Augmentation refers to the earlier onset of symptoms in the evening (or even the afternoon), increase in symptoms, and spread of symptoms to involve other extremities. Augmentation was specifically investigated in a controlled clinical trial over 26 weeks. Kaplan-Meier analysis of time to augmentation showed no significant difference between pramipexole (N = 152) and placebo groups (N = 149).
Driving and Using Machines: Patients should be aware of the fact that hallucinations can occur and may adversely affect their ability to drive.
Patients should be alerted to the potential sedating effects associated with pramipexole dihydrochloride monohydrate (Sifrol), including somnolence and the possibility of falling asleep while engaged in activities of daily living.
Use In Pregnancy & Lactation
Pregnancy: The effect on pregnancy and lactation has not been investigated in humans. Pramipexole was not teratogenic in rats and rabbits, but was embryotoxic in the rat at maternotoxic doses. Pramipexole dihydrochloride monohydrate (Sifrol) should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Lactation: The excretion of pramipexole dihydrochloride monohydrate (Sifrol) into the breast milk has not been studied in women. In rats, the concentration of drug was higher in the breast milk than in plasma. As pramipexole dihydrochloride monohydrate (Sifrol) treatment inhibits secretion of prolactin in humans inhibition of lactation is expected. In consequence, pramipexole dihydrochloride monohydrate (Sifrol) should not be used during breast-feeding.
Fertility: No studies on the effect on human fertility have been conducted. Animal studies did not indicate direct or indirect harmful effects with respect to male fertility.
Lactation: The excretion of pramipexole dihydrochloride monohydrate (Sifrol) into the breast milk has not been studied in women. In rats, the concentration of drug was higher in the breast milk than in plasma. As pramipexole dihydrochloride monohydrate (Sifrol) treatment inhibits secretion of prolactin in humans inhibition of lactation is expected. In consequence, pramipexole dihydrochloride monohydrate (Sifrol) should not be used during breast-feeding.
Fertility: No studies on the effect on human fertility have been conducted. Animal studies did not indicate direct or indirect harmful effects with respect to male fertility.
Adverse Reactions
Tabulated summary of adverse reactions: The following adverse reactions have been reported during use of pramipexole dihydrochloride monohydrate (Sifrol) in the clinical trials and in the post-marketing experience. (See Table 3.)
Description of selected adverse reactions: Sudden onset of sleep and somnolence: Patients treated with pramipexole have reported falling asleep during activities of daily living, including the operation of motor vehicles, which sometimes resulted in accidents. Some of them did not report a warning sign such as somnolence, which is a common occurrence in patients receiving pramipexole and which, according to the current knowledge of sleep physiology, always proceeds falling asleep. There was no clear relation to the duration of treatment. Some patients were taking other medication with potentially sedative properties. In most cases where information was available, there were no further episodes following reduction of dosage or termination of therapy.
Hypotension: The incidence of hypotension under pramipexole dihydrochloride monohydrate (Sifrol), compared to placebo treatment, was not increased. However, in individual patients, hypotension may occur at the beginning of treatment, especially if pramipexole dihydrochloride monohydrate (Sifrol) is titrated too rapidly.
Libido disorders: Pramipexole dihydrochloride monohydrate (Sifrol) may be associated with disorders of libido (increase or decrease).
Cardiac failure: In clinical studies and post-marketing experience cardiac failure has been reported in patients with pramipexole. In a pharmacoepidemiological study pramipexole use was associated with an increased risk of cardiac failure compared with non-use of pramipexole. A causal relationship between pramipexole and cardiac failure has not been demonstrated.
Drug Interactions
Pramipexole is bound to plasma proteins to a very low (<20%) extent and little biotransformation is seen in man. Therefore, interactions with other medication affecting plasma protein binding or elimination by biotransformation are unlikely.
Medication that inhibit the active renal tubular secretion of basic (cationic) drugs, such as cimetidine, or are themselves eliminated by active renal tubular secretion, may interact with pramipexole dihydrochloride monohydrate (Sifrol) resulting in reduced clearance of either or both medication. In case of concomitant treatment with these kinds of drugs (incl. amantadine) attention should be paid to signs of dopamine over stimulation, such as dyskinesias, agitation or hallucinations. In such cases a dose reduction is necessary.
Selegiline and levodopa do not influence the pharmacokinetics of pramipexole. The overall extent of absorption or elimination of levodopa is not changed by pramipexole. The interaction with anticholinergics and amantadine has not been examined.
As anticholinergics are mainly eliminated by hepatic metabolism, pharmacokinetic drug-drug interactions with pramipexole are rather unlikely. With amantadine, an interaction is possible via the same system of excretion in the kidney.
Antipsychotic medicinal products: Co-administration of antipsychotic medicinal products with pramipexole is not recommended, e.g. if dopamine-antagonistic effects can be expected. (See Precautions).
While increasing the dose of pramipexole dihydrochloride monohydrate (Sifrol) in Parkinson's disease patients it is recommended that the dosage of levodopa is reduced and the dosage of other antiparkinsonian medication kept constant.
Because of possible additive effects, caution should be advised when patients are taking other sedating medication or alcohol in combination with pramipexole dihydrochloride monohydrate (Sifrol) and when taking concomitant medication that increase plasma levels of pramipexole (e.g. cimetidine).
Medication that inhibit the active renal tubular secretion of basic (cationic) drugs, such as cimetidine, or are themselves eliminated by active renal tubular secretion, may interact with pramipexole dihydrochloride monohydrate (Sifrol) resulting in reduced clearance of either or both medication. In case of concomitant treatment with these kinds of drugs (incl. amantadine) attention should be paid to signs of dopamine over stimulation, such as dyskinesias, agitation or hallucinations. In such cases a dose reduction is necessary.
Selegiline and levodopa do not influence the pharmacokinetics of pramipexole. The overall extent of absorption or elimination of levodopa is not changed by pramipexole. The interaction with anticholinergics and amantadine has not been examined.
As anticholinergics are mainly eliminated by hepatic metabolism, pharmacokinetic drug-drug interactions with pramipexole are rather unlikely. With amantadine, an interaction is possible via the same system of excretion in the kidney.
Antipsychotic medicinal products: Co-administration of antipsychotic medicinal products with pramipexole is not recommended, e.g. if dopamine-antagonistic effects can be expected. (See Precautions).
While increasing the dose of pramipexole dihydrochloride monohydrate (Sifrol) in Parkinson's disease patients it is recommended that the dosage of levodopa is reduced and the dosage of other antiparkinsonian medication kept constant.
Because of possible additive effects, caution should be advised when patients are taking other sedating medication or alcohol in combination with pramipexole dihydrochloride monohydrate (Sifrol) and when taking concomitant medication that increase plasma levels of pramipexole (e.g. cimetidine).
Caution For Usage
Instructions for Use/Handling: N/A.
Storage
Store at temperatures not exceeding 30°C.
Action
Pharmacotherapeutic group: Dopamine agonist. ATC code: N04BC05.
Pharmacology: Pharmacodynamics: Mode of Action: Pramipexole, the active ingredient of pramipexole dihydrochloride monohydrate (Sifrol), is a dopamine agonist and binds with high selectivity and specificity to the dopamine D2 subfamily receptors and has a preferential affinity to D3 receptors; it has full intrinsic activity.
Pramipexole dihydrochloride monohydrate (Sifrol) alleviates parkinsonian motor deficits by stimulation of dopamine receptors in the striatum. Animal studies have shown that pramipexole inhibits dopamine synthesis, release, and turnover. Pramipexole protects dopamine neurones from degeneration in response to ischemia or methamphetamine neurotoxicity.
The precise mechanism of action of pramipexole dihydrochloride monohydrate (Sifrol) as a treatment for Restless Legs Syndrome is not known. Although the pathophysiology of Restless Legs Syndrome is largely unknown, neuropharmacological evidence suggests primary dopaminergic system involvement. Positron emission tomographic (PET) studies suggest that a mild striatal presynaptic dopaminergic dysfunction may be involved in the pathogenesis of Restless Legs Syndrome.
In vitro studies demonstrate that pramipexole protects neurones from levodopa neurotoxicity.
Clinical Trials: Parkinson's disease: Efficacy of pramipexole dihydrochloride monohydrate (Sifrol) in the controlled clinical trials was maintained for the duration of the trials, approximately six months. In open continuation trials lasting for more than three years there were no signs of decreasing efficacy.
Restless Legs Syndrome: The efficacy of pramipexole dihydrochloride monohydrate (Sifrol) was evaluated in four placebo controlled trials in approximately 1000 patients with moderate to very severe Restless Legs Syndrome. Efficacy was demonstrated in controlled trials in patients treated for up to 12 weeks and sustained efficacy was shown over a period of 9 months. The efficacy of Pramipexole dihydrochloride monohydrate (Sifrol) was maintained during open continuation trials lasting for up to 1 year. In a placebo controlled clinical trial over 26 weeks, the efficacy of pramipexole was confirmed in patients with moderate to severe RLS.
Pharmacokinetics: Absorption: Pramipexole is rapidly and completely absorbed following oral administration. The absolute bioavailability is greater than 90%.
Tablets: The maximum plasma concentrations occur between 1 and 3 hours. The rate of absorption is reduced by food intake but not the overall extent of absorption.
Pramipexole shows linear kinetics and a relatively small inter-patient variation of plasma levels irrespective of the pharmaceutical form.
Distribution: In humans the protein binding of pramipexole is very low (<20%) and the volume of distribution is large (400 L). High brain tissue concentrations were observed in the rat (approx. 8-fold compared to plasma).
Biotransformation: Pramipexole is metabolised in man only to a small extent.
Elimination: Renal excretion of unchanged pramipexole is the major route of elimination and accounts for about 80% of dose. Approx. 90% of a 14C-labelled dose is excreted through the kidneys while less than 2% is found in the faeces. The total clearance of pramipexole is approx. 500 mL/min and the renal clearance is approx. 400 mL/min. The elimination half-life (t1/2) varies from 8 hours in the young to 12 hours in the elderly.
Toxicology: Repeat-dose toxicity: Repeated dose toxicity studies showed that pramipexole exerted functional effects, mainly involving the CNS and, in the rat, the female reproductive system, probably resulting from an exaggerated pharmacodynamic effect of pramipexole.
Decreases in diastolic and systolic pressure and heart rate were noted in the minipig, and a tendency to a hypotensive effect was discerned in the monkey.
Reproductive and developmental toxicity: The potential effects of pramipexole on reproductive function have been investigated in rats and rabbits. Pramipexole was not teratogenic in rats and rabbits but was embryotoxic in the rat at maternally toxic doses. Due to the hypoprolactinaemic effect of the compound and the special role of prolactin in reproductive function in the female rat, the effects of pramipexole on pregnancy and female fertility were not fully elucidated.
A delay in sexual development (i.e. preputial separation and vaginal opening) was observed in rats. The relevance for humans is unknown.
Genotoxicity and carcinogenicity: Pramipexole was not genotoxic. In a carcinogenicity study, male rats developed Leydig cell hyperplasia and adenomas, explained by the prolactin-inhibiting effect of pramipexole. This finding is not clinically relevant to man. The same study also showed that, at doses of 2 mg/kg (of the salt form) and higher, pramipexole was associated with retinal degeneration in albino rats. The latter finding was not observed in pigmented rats, nor in a 2-year albino mouse carcinogenicity study, or in any other species investigated.
Pharmacology: Pharmacodynamics: Mode of Action: Pramipexole, the active ingredient of pramipexole dihydrochloride monohydrate (Sifrol), is a dopamine agonist and binds with high selectivity and specificity to the dopamine D2 subfamily receptors and has a preferential affinity to D3 receptors; it has full intrinsic activity.
Pramipexole dihydrochloride monohydrate (Sifrol) alleviates parkinsonian motor deficits by stimulation of dopamine receptors in the striatum. Animal studies have shown that pramipexole inhibits dopamine synthesis, release, and turnover. Pramipexole protects dopamine neurones from degeneration in response to ischemia or methamphetamine neurotoxicity.
The precise mechanism of action of pramipexole dihydrochloride monohydrate (Sifrol) as a treatment for Restless Legs Syndrome is not known. Although the pathophysiology of Restless Legs Syndrome is largely unknown, neuropharmacological evidence suggests primary dopaminergic system involvement. Positron emission tomographic (PET) studies suggest that a mild striatal presynaptic dopaminergic dysfunction may be involved in the pathogenesis of Restless Legs Syndrome.
In vitro studies demonstrate that pramipexole protects neurones from levodopa neurotoxicity.
Clinical Trials: Parkinson's disease: Efficacy of pramipexole dihydrochloride monohydrate (Sifrol) in the controlled clinical trials was maintained for the duration of the trials, approximately six months. In open continuation trials lasting for more than three years there were no signs of decreasing efficacy.
Restless Legs Syndrome: The efficacy of pramipexole dihydrochloride monohydrate (Sifrol) was evaluated in four placebo controlled trials in approximately 1000 patients with moderate to very severe Restless Legs Syndrome. Efficacy was demonstrated in controlled trials in patients treated for up to 12 weeks and sustained efficacy was shown over a period of 9 months. The efficacy of Pramipexole dihydrochloride monohydrate (Sifrol) was maintained during open continuation trials lasting for up to 1 year. In a placebo controlled clinical trial over 26 weeks, the efficacy of pramipexole was confirmed in patients with moderate to severe RLS.
Pharmacokinetics: Absorption: Pramipexole is rapidly and completely absorbed following oral administration. The absolute bioavailability is greater than 90%.
Tablets: The maximum plasma concentrations occur between 1 and 3 hours. The rate of absorption is reduced by food intake but not the overall extent of absorption.
Pramipexole shows linear kinetics and a relatively small inter-patient variation of plasma levels irrespective of the pharmaceutical form.
Distribution: In humans the protein binding of pramipexole is very low (<20%) and the volume of distribution is large (400 L). High brain tissue concentrations were observed in the rat (approx. 8-fold compared to plasma).
Biotransformation: Pramipexole is metabolised in man only to a small extent.
Elimination: Renal excretion of unchanged pramipexole is the major route of elimination and accounts for about 80% of dose. Approx. 90% of a 14C-labelled dose is excreted through the kidneys while less than 2% is found in the faeces. The total clearance of pramipexole is approx. 500 mL/min and the renal clearance is approx. 400 mL/min. The elimination half-life (t1/2) varies from 8 hours in the young to 12 hours in the elderly.
Toxicology: Repeat-dose toxicity: Repeated dose toxicity studies showed that pramipexole exerted functional effects, mainly involving the CNS and, in the rat, the female reproductive system, probably resulting from an exaggerated pharmacodynamic effect of pramipexole.
Decreases in diastolic and systolic pressure and heart rate were noted in the minipig, and a tendency to a hypotensive effect was discerned in the monkey.
Reproductive and developmental toxicity: The potential effects of pramipexole on reproductive function have been investigated in rats and rabbits. Pramipexole was not teratogenic in rats and rabbits but was embryotoxic in the rat at maternally toxic doses. Due to the hypoprolactinaemic effect of the compound and the special role of prolactin in reproductive function in the female rat, the effects of pramipexole on pregnancy and female fertility were not fully elucidated.
A delay in sexual development (i.e. preputial separation and vaginal opening) was observed in rats. The relevance for humans is unknown.
Genotoxicity and carcinogenicity: Pramipexole was not genotoxic. In a carcinogenicity study, male rats developed Leydig cell hyperplasia and adenomas, explained by the prolactin-inhibiting effect of pramipexole. This finding is not clinically relevant to man. The same study also showed that, at doses of 2 mg/kg (of the salt form) and higher, pramipexole was associated with retinal degeneration in albino rats. The latter finding was not observed in pigmented rats, nor in a 2-year albino mouse carcinogenicity study, or in any other species investigated.
MedsGo Class
Antiparkinsonian Drugs
Features
Brand
Sifrol
Full Details
Dosage Strength
250 mcg
Drug Ingredients
- Pramipexole
Drug Packaging
Tablet 1's
Generic Name
Pramipexole
Dosage Form
Tablet
Registration Number
DR-XY27922
Drug Classification
Prescription Drug (RX)
Please sign in so that we can notify you about a reply